This section of pediculosis.com is devoted to news about product launches, updates and withdrawals.
A study undertaken to determine the ovicidal efficacy of abametapir against eggs of both human head and body lice has revealed that abametaphir has an 100% ovicidal activity in vitro assessments and therefore able to inhibit hatching of both head and body louse eggs if used in specific concetrations.
The head lice brand Hedrin has announced the launch of a Stubborn Egg Loosening Lotion and suggested that this new addition to the Hedrin family would make it easy to remove dead eggs from the hair after treatment.
New commentary warns of the risks of excessive use of ivermectin for unauthorized groups.
A new treated coat-stand is being trialled in France, aiming to reduce the spread of head-lice in schools.
A summary of recent pediculosis product news.
The anti-lice product DeOvo, developed by Hatchtech Pty Ltd, has successfully completed its end-of-phase II consultations with the FDA.
Sanofi Pasteur announced this week that Sklice, their ivermectin-based head lice treatment is now commercially available by prescription in the US.